利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.031 秒)

    Method of treating inflammation by blocking ELAM-1 receptor sites
    4.
    发明授权
    Method of treating inflammation by blocking ELAM-1 receptor sites 失效
    通过阻断ELAM-1受体位点治疗炎症的方法

    公开(公告)号：US5428025A

    公开(公告)日：1995-06-27

    申请号：US844101

    申请日：1992-03-02

    申请人： Brian K. Brandley ,  Michael Tiemeyer ,  Stuart J. Swiedler ,  Margaret Moreland ,  Hans Schweingruber

    发明人： Brian K. Brandley ,  Michael Tiemeyer ,  Stuart J. Swiedler ,  Margaret Moreland ,  Hans Schweingruber

    IPC分类号： A61K31/70 ,  A61K51/08 ,  C07H13/04 ,  C07K14/705 ,  G01N33/569 ,  A01N43/04 ,  A61K31/73

    CPC分类号： C07H13/04 ,  A61K31/70 ,  A61K47/48092 ,  A61K51/08 ,  C07K14/70564 ,  G01N33/56972 ,  A61K2123/00

    摘要： Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of F and G is hydrogen and one is an N-acetyl neuraminic acid residue on the terminal unit and are both hydrogen on any other unit; J is hydrogen, a lactosylceramide or a linking group and K is hydrogen or a fucose residue and n is an integer of from 1 to 10 (preferably 3 or 4) with the proviso that n and K are defined such that at least one K is a fucose residue.

    摘要翻译： 公开了结合内皮白细胞粘附分子-1（ELAM-1）的N-乙酰乳糖胺形式的配体。 配体化合物可以配制成药物组合物和/或用于缓解炎症和测定（定性）和量的（定量）ELAM-1的存在的药物组合物和/或测定组合物，从而确定炎症的存在，位置和程度。 配体由通式结构式I包括如下：其中F和G中的一个是氢，一个是末端单元上的N-乙酰神经氨酸残基，并且在任何其它单元上都是氢; J是氢，乳糖神经酰胺或连接基团，K是氢或岩藻糖残基，n是1至10（优选3或4）的整数，条件是n和K被定义为至少一个K是 岩藻糖残基。

    Method of determining a site of inflammation utilizing elam-1 ligands
    5.
    发明授权
    Method of determining a site of inflammation utilizing elam-1 ligands 失效
    使用elam-1配体测定炎症部位的方法

    公开(公告)号：US5143712A

    公开(公告)日：1992-09-01

    申请号：US637868

    申请日：1991-01-07

    申请人： Brian K. Brandley ,  Michael Tiemeyer ,  Stuart J. Swiedler ,  Margaret Moreland ,  Hans Schweingruber

    发明人： Brian K. Brandley ,  Michael Tiemeyer ,  Stuart J. Swiedler ,  Margaret Moreland ,  Hans Schweingruber

    IPC分类号： A61K31/70 ,  A61K51/08 ,  C07H13/04 ,  C07K14/705 ,  G01N33/569

    CPC分类号： C07H13/04 ,  A61K31/70 ,  A61K47/48092 ,  C07K14/70564 ,  G01N33/56972 ,  A61K2123/00

    摘要： Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of A and B is hydrogen and one is an N-acetyl neuraminic acid residue; D and E are each independently hydrogen or a fucose residue; n is an integer of from 0 to 10 with the proviso that if n is 0, E is a fucose residue; F is hydrogen, a lactosylceramide residue or a linking group; and molecules equivalent to a compound of formula I regarding its ability to bind to an ELAM-1 receptor to the same degree as a compound of formula I.

    摘要翻译： 公开了结合内皮白细胞粘附分子-1（ELAM-1）的N-乙酰乳糖胺形式的配体。 配体化合物可以配制成药物组合物和/或用于缓解炎症和测定（定性）和量的（定量）ELAM-1的存在的药物组合物和/或测定组合物，从而确定炎症的存在，位置和程度。 配体由通式结构式I包括如下：其中A和B之一是氢，一个是N-乙酰神经氨酸残基; D和E各自独立地为氢或岩藻糖残基; n为0至10的整数，条件是如果n为0，则E为岩藻糖残基; F是氢，乳糖神经酰胺残基或连接基团; 以及与式I化合物相当于其与式I化合物相同程度结合ELAM-1受体的能力的分子。

    Method of determining a cite of inflammation utilizing elam-1 ligands site
    7.
    发明授权
    Method of determining a cite of inflammation utilizing elam-1 ligands site 失效
    确定使用ELAM-1配置站点的使用方法

    公开(公告)号：US5211936A

    公开(公告)日：1993-05-18

    申请号：US559836

    申请日：1990-07-30

    申请人： Brian K. Brandley ,  Michael Tiemeyer ,  Stuart J. Swiedler ,  Margaret Moreland ,  Hans Schweingruber

    发明人： Brian K. Brandley ,  Michael Tiemeyer ,  Stuart J. Swiedler ,  Margaret Moreland ,  Hans Schweingruber

    IPC分类号： A61K31/70 ,  A61K51/08 ,  C07H13/04 ,  C07K14/705 ,  G01N33/569

    CPC分类号： C07H13/04 ,  A61K31/70 ,  A61K47/48092 ,  A61K51/08 ,  C07K14/70564 ,  G01N33/56972 ,  A61K2123/00

    摘要： Ligands in the form of N-acetyllactosamines which bind to endothelial leukocyte adhesion molecule-1 (ELAM-1) are disclosed. The ligand compounds can be formulated into pharmaceutical compositions and/or assay compositions used to alleviate inflammation and assay for the presence of (qualitative) and amount of (quantitative) ELAM-1 and thereby determine the presence, location and degree of inflammation. The ligands are encompassed by general structural formula I as follows: ##STR1## wherein one of F and G is hydrogen and one is an N-acetyl neuraminic acid residue on the terminal unit and are both hydrogen on any other unit; J is hydrogen, a lactosylceramide or a linking group and K is hydrogen or a fucose residue and n is an integer of from 1 to 10 (preferably 3 or 4) with the proviso that n and K are defined such that at least one K is a fucose residue.

    摘要翻译： 公开了结合内皮白细胞粘附分子-1（ELAM-1）的N-乙酰乳糖胺形式的配体。 配体化合物可以配制成药物组合物和/或用于缓解炎症和测定（定性）和量的（定量）ELAM-1的存在的药物组合物和/或测定组合物，从而确定炎症的存在，位置和程度。 配体由通式结构式I包括如下：其中F和G中的一个是氢，一个是末端单元上的N-乙酰神经氨酸残基，并且在任何其它单元上都是氢; J是氢，乳糖神经酰胺或连接基团，K是氢或岩藻糖残基，n是1至10（优选3或4）的整数，条件是n和K被定义为至少一个K是 岩藻糖残基。